Avidity Biosciences Inc reports results for the quarter - Earnings Summary

Avidity Biosciences

08/11/2024 21:04

* Avidity Biosciences Inc  RNA.OQ  reported a quarterly
adjusted
loss of 65 cents​​ per share for the quarter , higher than the
same quarter last year, when the company reported EPS of -71
cents.  The mean expectation of ten analysts for the quarter was
for a loss of 71 cents per share. Wall Street expected
results to range from -94 cents to -46 cents per share.
    * Revenue fell 17.1% to $2.34 million from a year ago;
analysts
expected $4.27 million. 
    * Avidity Biosciences Inc's reported EPS for the quarter was
a
loss of 65 cents​.
    * The company reported a quarterly loss of $80.4 million.
    * Avidity Biosciences Inc shares had risen by 3.4% this
quarter and gained 425.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 11.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Avidity
Biosciences Inc is $64.00 
This summary was machine generated from LSEG data November 8 at
09:03 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.71          -0.65          Beat
 Jun. 30 2024      -0.79          -0.65          Beat
 Mar. 31 2024      -0.78          -0.79          Missed
 Dec. 31 2023      -0.66          -0.79          Missed